uniQure files AMT-130 in U.S. and U.K. as Huntington’s gene therapy reaches regulators

uniQure N.V. (NASDAQ: QURE) has submitted a Biologics License Application to the U.S. Food and Drug Administration seeking accelerated approval for ifezuntirgene inilparvovec, better known as AMT-130, while simultaneously filing a Marketing Authorisation Application with the United Kingdom’s Medicines and Healthcare products Regulatory Agency. The submissions move AMT-130 beyond regulatory planning into an actual approval process for a disease in which no currently approved therapy has been shown to slow progression. uniQure has requested Priority Review in the United States, which could shorten the FDA review cycle to six months after the agency completes its initial 60-day filing review if the request is granted. The filing is supported primarily by three-year Phase 1/2 evidence compared against an external natural-history control, making the central regulatory question unusually consequential: whether a small, nontraditional gene-therapy dataset is sufficiently persuasive to support accelerated approval in a relentlessly progressive neurological disease.

The filing represents a genuinely new milestone from the earlier regulatory discussions that placed AMT-130 on a possible submission path. In June, the FDA told uniQure that the three-year Phase 1/2 analysis could serve as the primary basis for a BLA under the accelerated-approval pathway, provided the parties aligned around a confirmatory study. The September submission means uniQure has now acted on that agreement and transferred the next major decision to regulators in the United States and United Kingdom.

What evidence is uniQure asking the FDA to accept for AMT-130 accelerated approval?

The application relies on three-year results from uniQure’s ongoing Phase 1/2 program compared with a propensity-score matched external control drawn from the Enroll-HD natural-history database. The company has previously reported that high-dose AMT-130 slowed progression on a composite measure of Huntington’s disease by approximately 75% relative to the matched external control at three years. That result generated substantial interest because Huntington’s disease currently has treatments for symptoms but no approved therapy proven to alter the underlying course of neurodegeneration.

The underlying clinical program remains small relative to conventional late-stage neurological trials. The U.S. randomized study enrolled 26 patients, including six treated at low dose, ten at high dose and ten assigned initially to a sham surgical procedure, while the European open-label study enrolled another 13 patients. Additional cohorts have evaluated immunosuppression and high-dose treatment in patients with lower striatal volumes, giving regulators a wider safety dataset but still leaving the overall treated population far below the hundreds or thousands of patients common in traditional pivotal development.

That is why reliance on the external control is so important. Natural-history databases can help regulators understand expected disease progression where conducting large sham-controlled surgical trials is difficult or ethically complicated, but they also introduce uncertainty around patient matching, changes in clinical care and differences between observed trial patients and historical populations. The FDA’s willingness to allow the BLA submission does not guarantee that the agency will ultimately consider those comparisons robust enough for approval.

How does AMT-130 attempt to slow Huntington’s disease with one treatment?

AMT-130 uses uniQure’s miQURE gene-silencing platform and contains a microRNA designed to suppress the huntingtin gene and reduce production of both full-length mutant huntingtin and the potentially toxic exon 1 protein fragment. Rather than circulating systemically, the gene therapy is administered once directly into the striatum through MRI-guided, convection-enhanced stereotactic neurosurgery. The procedure targets the caudate and putamen, brain structures deeply involved in the motor and cognitive deterioration associated with Huntington’s disease.

A one-time therapy could offer an obvious adherence advantage if the biological effect proves durable, but intracranial delivery creates a much higher treatment threshold than oral or infused medicines. Commercial success would require specialized neurosurgical centers, imaging infrastructure, careful patient selection and confidence that the expected disease-modifying benefit outweighs the procedural and gene-therapy risks. That makes durability especially important because patients and payers are unlikely to accept the burden of brain surgery for a temporary or modest effect.

The FDA has granted AMT-130 Breakthrough Therapy, Regenerative Medicine Advanced Therapy and Fast Track designations. Those regulatory statuses facilitate communication and expedited development but do not establish efficacy, leaving the submitted evidence and upcoming longer-term data as the determinants of whether the therapy can move from an exceptional regulatory pathway into actual clinical use.

Why is the confirmatory trial central to AMT-130’s accelerated approval strategy?

Accelerated approval can permit earlier market access based on evidence considered reasonably likely to predict clinical benefit, but sponsors are generally required to verify that benefit through post-approval studies. uniQure has been discussing a confirmatory design that could compare treated patients against people receiving standard care rather than requiring another sham neurosurgical control. That approach could make recruitment more practical while avoiding subjecting control patients to invasive brain surgery purely for trial blinding.

The confirmatory study nevertheless carries meaningful financial and regulatory consequences. If AMT-130 receives accelerated approval, failure to complete the required study or inability to confirm benefit could threaten continued authorization. uniQure must therefore prepare for commercialization and post-approval clinical development at the same time, creating a substantially different cost structure from a biotechnology company simply waiting for an FDA decision.

The company has indicated that it intends to provide four-year Phase 1/2 data before the end of the third quarter. Those results could become important during regulatory review because durability is one of the most consequential questions surrounding a one-time gene therapy intended to alter a lifelong neurodegenerative disease.

Does uniQure have enough cash to carry AMT-130 through review and launch preparation?

uniQure ended June with approximately $413 million of cash and cash equivalents plus $397 million of current investment securities, giving it more than $800 million across those two major liquidity categories. The company strengthened its balance sheet during the first half through a follow-on equity offering that generated approximately $243 million of net proceeds, while operating activities remained cash consuming as clinical and regulatory spending continued.

That balance sheet gives uniQure more flexibility than it had during earlier stages of the AMT-130 program, but gene-therapy commercialization can be expensive. Manufacturing, treatment-center qualification, surgical training, payer engagement and a confirmatory clinical trial can all consume substantial capital before the product achieves meaningful revenue. The ability to finance those activities without an immediate equity offering reduces one risk but does not make regulatory success less important.

AMT-130 also dominates the company’s near-term valuation despite additional programs in epilepsy and Fabry disease. The earlier BNT coverage of AMT-260 showed how uniQure is trying to create a broader neurological gene-therapy platform, but none of those assets is close enough to commercialization to offset a major AMT-130 setback. The BLA submission therefore concentrates rather than reduces near-term regulatory sensitivity.

Why did QURE shares decline after the regulatory filing?

uniQure shares closed at $46.23 on September 2, down 3.41% despite the filing announcement, and continued declining to $44.86 on September 3 and $44.50 on September 4. That put the shares about 8.7% below their August 28 close of $48.72 and substantially below the 52-week high of $71.50. The reaction contrasts with an initial premarket gain and suggests investors viewed the submission as largely expected after the FDA’s June regulatory guidance rather than as a fresh increase in approval probability.

There may also be a straightforward expectations issue. AMT-130’s strong three-year result and earlier FDA discussions had already driven a major rerating in QURE, meaning the actual paperwork submission did not resolve the difficult questions around external controls, durability and confirmatory evidence. Investors now need the FDA to accept the BLA for filing, decide whether to grant Priority Review and eventually determine whether the total evidence supports accelerated approval.

For uniQure, the regulatory clock has finally started in earnest. Filing a BLA does not mean AMT-130 is approved, and filing acceptance itself still has to occur. It does mean the first potential disease-modifying Huntington’s gene therapy has moved from discussing an unconventional approval route to testing whether regulators will actually use it.